CC-42344 / Cocrystal Pharma - LARVOL DELTA

Influenza Viral Challenge Study of CC-42344 in Healthy Participants (clinicaltrials.gov) - P2 | N=78 | Completed | Sponsor: Cocrystal Pharma, Inc. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Influenza Viral Challenge Study of CC-42344 in Healthy Participants (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Cocrystal Pharma, Inc.

New P2 trial • Infectious Disease • Influenza • Respiratory Diseases

CC-42344 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Cocrystal Pharma, Inc. | N=56 ➔ 80

Enrollment change • Infectious Disease • Influenza • Respiratory Diseases

First-in-Human Study of CC-42344, a Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor (ISIRV-AVG 2023) - No abstract available

P1 data • Infectious Disease • Influenza • Respiratory Diseases

CC-42344 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Cocrystal Pharma, Inc. | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Mar 2023 | Trial primary completion date: Sep 2022 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

CC-42344 Safety Study in Healthy Participants (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Cocrystal Pharma, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases

CC-42344 Phase 1 Safety and PK Study in Healthy Participants (clinicaltrials.gov) - P1; N=56; Not yet recruiting; Sponsor: Cocrystal Pharma, Inc.

New P1 trial • Infectious Disease • Respiratory Diseases